VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AGIO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AGIOAgios Pharmaceuticals, Inc.
$29.68$1.8B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. AGIO
  4. Financial Ratios

Agios Pharmaceuticals, Inc. (AGIO) Financial Ratios

Latest Ratios: P/E Ratio -4.8x · EV/EBITDA N/A · ROE -30.2%. (2011–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

AGIO Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.8B$1.6B$1.9B$1.2B$1.5B$2.0B$3.0B$2.9B$2.6B$2.7B$1.6B
Enterprise Value$1.7B$1.5B$1.9B$1.2B$1.5B$1.9B$3.0B$2.9B$1.8B$2.1B$1.1B
P/E Ratio →-4.75—2.82————————
P/S Ratio12.5329.2152.1246.21108.04——24.3028.0561.9223.36
P/B Ratio1.441.321.231.531.401.547.484.473.857.094.55
P/FCF——————————57.00
P/OCF——————————42.34

P/E links to full P/E history page with 30-year chart

AGIO EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—28.3051.5945.60104.28——24.5719.5248.7215.15
EV / EBITDA———————————
EV / EBIT——2.62————————
EV / FCF——————————36.97

AGIO Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin78.7%78.7%88.6%64.6%88.0%——98.9%98.5%-580.5%-215.0%
Operating Margin-873.9%-873.9%-1166.5%-1459.5%-2732.1%——-361.6%-384.0%-745.8%-287.6%
Net Profit Margin-764.0%-764.0%1845.9%-1312.6%-1627.8%——-349.0%-366.6%-731.6%-284.0%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-30.2%-30.2%57.3%-36.8%-19.4%189.7%-63.0%-62.0%-65.1%-85.7%-56.4%
ROA-27.9%-27.9%51.8%-32.4%-17.3%140.1%-37.5%-47.0%-47.0%-51.0%-38.2%
ROIC-26.6%-26.6%-27.6%-31.9%-26.1%-36.3%-48.0%-115.1%———
ROCE-33.8%-33.8%-34.7%-38.3%-30.5%-35.4%-43.2%-54.6%-56.4%-61.1%-44.8%

AGIO Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.030.030.040.090.080.080.260.18———
Debt / EBITDA———————————
Net Debt / Equity—-0.04-0.01-0.02-0.05-0.08-0.060.05-1.17-1.51-1.60
Net Debt / EBITDA———————————
Debt / FCF——————————-20.02
Interest Coverage——————-18.47————

Net cash position: cash ($89M) exceeds total debt ($40M)

AGIO Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio11.4611.4611.9012.2713.3017.796.746.596.564.696.33
Quick Ratio11.0611.0611.5611.9913.1617.796.746.516.556.206.70
Cash Ratio10.3910.3911.0111.4312.5017.056.076.088.615.986.49
Asset Turnover—0.040.020.030.01——0.130.110.070.11
Inventory Turnover0.350.350.150.500.20——0.181.61——
Days Sales Outstanding—71.4641.0938.2456.54——47.4240.3831.1443.42

AGIO Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield——35.4%————————
FCF Yield——————————1.8%
Buyback Yield0.0%0.0%0.0%0.0%0.0%40.4%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%40.4%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$58M$58M$56M$55M$60M$69M$60M$57M$47M$39M

Key Metrics

Growth RegimeExpanding
ProfitabilityWeak
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Persistent operating losses and cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Cash-Plus-Pipeline Valuation Despite Losses

Based on reported figures, AGIO trades at a P/S of 12.42 and P/B of 1.43 because its P/E of -4.71 is meaningless, so the market appears to be pricing the pipeline rather than current earnings against roughly $54.0M of TTM revenue.

The negative P/E reflects a net loss so large relative to earnings that the multiple carries no analytical information, so valuation must be anchored to sales and book value instead. A P/S of 12.42 implies investors are paying a substantial premium on a revenue base still under $60M per quarter, which suggests they are capitalizing expected PYRUKYND growth and label expansion. The P/B of 1.43 sits modestly above book, but book value is itself eroding through accumulated losses, so investors should monitor whether the premium compresses as equity declines.

Gross Margin Strength Versus Operating Deficit

As reported in financial statements, AGIO's gross margin expanded from 64.2% in 2024Q2 to 95.4% in 2026Q3, yet the operating margin remained at -139.3% in the latest quarter, indicating gross profit is far too small to absorb the cost base.

The gross margin trajectory suggests the orphan-drug pricing model is structurally sound, since manufacturing costs appear low relative to realized price. However, operating margin volatility, moving from -2.5% in 2026Q2 to -139.3% in 2026Q3, indicates quarterly expense timing or revenue recognition may be distorting the picture and should be treated cautiously. Net margin of -117.4% in the latest quarter suggests operating leverage has not yet emerged, and investors should watch whether operating expenses stabilize relative to revenue.

Minimal Debt Limits Solvency Pressure

According to recent SEC filings, AGIO's debt-to-equity ratio fell from 0.10 to 0.03 over the period, suggesting leverage is not the primary balance sheet concern, though interest coverage cannot be assessed from the data provided.

A debt-to-equity decline from 0.10 in 2024Q2 to 0.03 indicates the company has largely deleveraged, which may reduce refinancing and covenant risk. The absence of a reported interest coverage ratio means debt service cannot be evaluated directly, and no comfort should be inferred from that gap. The more relevant risk appears to be equity erosion, as negative ROE of -6.5% in the latest quarter continues to consume book value.

Current Ratio Masks Thin Cash Cushion

Based on reported figures, AGIO's current ratio of 9.69 and quick ratio of 9.21 in 2026Q3 appear strong, but cash of roughly $128.5M against quarterly operating burn well above that level suggests a limited runway.

Current and quick ratios near 9 to 10 are high, but they are dominated by liquid assets being consumed by operations rather than representing durable financial strength. Because quick and current ratios are nearly identical, inventory appears immaterial to liquidity, which is consistent with a small-molecule product where working capital sits largely in receivables and cash. Under severe stress, the relevant question is whether cash reserves can fund operations through the next pipeline catalyst, which warrants further investigation given the reported cash discrepancy flagged in prior analysis.

Working Capital Cycle Stretched by Inventory

As reported in financial statements, AGIO's inventory days of roughly 1,239 and cash conversion cycle of 616 days in 2026Q3 suggest significant working capital tied up in slow-moving stock relative to sales.

Inventory days at extreme levels may indicate a very small revenue base relative to stocked inventory or timing effects from production batches, which could reflect a mismatch between manufacturing volume and patient demand. DPO of 661 days is unusually high and implies heavy reliance on supplier credit, which may be sustainable but warrants monitoring. Asset turnover of 0.05 suggests the asset base is heavily underutilized relative to revenue, consistent with a company still building commercial scale.

Ratio Optics Versus Cash Reality

Based on reported figures, the 9.69 current ratio and 0.03 debt-to-equity may understate risk, since operating cash flow has been negative in every quarter shown and stock-based compensation of roughly $11M to $17M per quarter is added back in reported cash flow.

Strong headline liquidity and low leverage can be misleading for a burning biotech, because balance sheet ratios capture a snapshot rather than the rate of cash consumption. Adding back stock-based compensation flatters operating cash flow, and treating it as a real economic cost would likely deepen the apparent burn. Investors should therefore weight free cash flow margin, which ranged from -5.8% to -130.8% across recent quarters, more heavily than static balance sheet ratios when judging funding needs.

Download Financial Ratios Data

Includes 30+ ratios · 15 years · Updated daily

Consensus & Technical Research Suite
Open AGIO Terminal

AGIO Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AGIO — Frequently Asked Questions

Quick answers to the most common questions about buying AGIO stock.

What is Agios Pharmaceuticals, Inc.'s P/E ratio?

Agios Pharmaceuticals, Inc.'s current P/E ratio is -4.8x. The historical average is 2.8x.

What is Agios Pharmaceuticals, Inc.'s ROE?

Agios Pharmaceuticals, Inc.'s return on equity (ROE) is -30.2%. The historical average is -22.8%.

Is AGIO stock overvalued?

Based on historical data, Agios Pharmaceuticals, Inc. is trading at a P/E of -4.8x. Compare with industry peers and growth rates for a complete picture.

What are Agios Pharmaceuticals, Inc.'s profit margins?

Agios Pharmaceuticals, Inc. has 78.7% gross margin and -873.9% operating margin.